Valiant Organics Ltd (VALIANTORG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Valiant Organics Ltd on NSE and BSE, with an AI summary of each filing.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 05 Nov 2026, 5:30 am
Valiant Organics Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
Valiant Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited financial results ....
Intimation · 05 Nov 2026, 5:30 am
Valiant Organics Schedules Board Meeting to Consider Q2 FY27 Financial Results Valiant Organics Limited announced that its Board of Directors will meet on 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities, which has been closed since the earlier intimation on 28th Sep'26, will remain closed until 7th Nov'26.
Please find our intimation in captioned subject
Others (Uncategorized) · 01 Oct 2026, 11:25 pm
Valiant Organics Receives Income Tax Rectification Order for Rs. 22.15 Lakh Valiant Organics received a physical copy of an Income Tax rectification order dated 8th Jul'26 on 1st Oct'26 under Section 154 for AY 2015-16, originally issued to amalgamated entity Amarjyot Chemical Limited. The Centralized Processing Centre, Bengaluru, rectified computation errors, determining a net payable amount of Rs. 22,15,080. The order carries no penalties or operational disruptions. The company is evaluating the order to determine appropriate steps.
Please find our intimation in captioned subject
Change in Management · 30 Sept 2026, 11:07 pm
Valiant Organics Shareholders Approve Re-Appointment of Managing Director and Board Members Shareholders of Valiant Organics Limited approved key board re-appointments at the 21st AGM held on 29th Sep'26. Sathiababu K. Kallada has been re-appointed as Managing Director for a three-year term effective from 24th May'27 to 23rd May'30, not liable to retire by rotation. Additionally, shareholders approved the rotational re-appointments of Nemin M. Savadia as Executive Director and Santosh S. Vora as Non-Executive Director, both effective from 29th Sep'26. None of the directors are related or debarred by SEBI.
Please find E-voting and Scrutinizer report of 21st Annual General Meeting of the Company
Annual General Meeting · 30 Sept 2026, 11:05 pm
Please find enclosed herewith presentation made to the shareholders at 21st Annual General Meeting of the Company.
Investor Presentation · 29 Sept 2026, 9:51 pm
Please find enclosed the Proceedings of the 21st Annual General Meeting of the Company held on today i.e. Tuesday, September 29, 2026.
Annual General Meeting · 29 Sept 2026, 9:47 pm
Please find attached Business Responsibility and Sustainability Report for the year ended March 31, 2026.
Others (Uncategorized) · 06 Sept 2026, 12:12 am
Valiant Organics Releases FY26 Business Responsibility and Sustainability Report Valiant Organics reported a turnover of Rs. 738.38 Cr and net worth of Rs. 696.85 Cr for FY'26, with Dyes & Pigments (45%), Agro-chemicals (24%), and Pharmaceuticals (21%) driving operations across six plants. Related-party transactions accounted for 64.59% of purchases and 42.85% of sales. Sustainability capex dropped to 3.46% of total capex from 67.76% in FY'25. Energy consumption totaled 2,161.42 TJ with Scope 1 and Scope 2 emissions at 150,072.61 MT and 29,077.66 MT CO2e, respectively. Accounts payable stood at 128 days versus 121 days YoY.
Please find attached the notice of the 21st Annual General Meeting of the Company scheduled to be held on Tuesday, September 29, 2026 at 11.30 A.M. (IST).
Annual General Meeting · 06 Sept 2026, 12:10 am
Please find attached the Annual Report of the Company for the FY 2025-26
Others (Uncategorized) · 06 Sept 2026, 12:07 am
Please find our intimation in captioned subject.
Investor Presentation · 21 Aug 2026, 8:26 pm
Valiant Organics: Q1-FY27 Sees Strong Margin Expansion and Revenue Growth Valiant Organics reported strong Q1-FY27 results, with consolidated revenue up 13.3% YoY to INR 2,315 Mn. EBITDA grew 67.7% YoY to INR 416 Mn, with margins expanding significantly to 17.97% from 12.13% in Q1-FY26, the highest in six quarters. This was driven by lower raw material costs and operating leverage. Consolidated PAT was INR 293 Mn, with PAT margin at 12.66% vs. 4.01% YoY. The company reported a consolidated EPS of INR 10.44 for the quarter ended 30th Jun'26.
Publication of financial results for the quarter ended June 30, 2026 and Notice to shareholders for the intimation of transfer of unclaimed/unpaid dividend to IEPF.
Dividend · 14 Aug 2026, 5:12 pm
Valiant Organics Q1 FY27 Results and Shareholder Notice Valiant Organics has published its financial results for the quarter ending 30th Jun'26. The company also notified shareholders that the unclaimed final dividend for FY19 and interim dividend for FY20 will be transferred to the Investor Education and Protection Fund (IEPF). Shareholders must lodge claims by 30th Oct'26 to prevent the transfer. The deadlines for transfer to the IEPF are 6th Nov'26 for the FY19 dividend and 15th Dec'26 for the FY20 dividend, respectively.
Please find our intimation in the captioned subject
Others (Uncategorized) · 12 Aug 2026, 10:15 pm
Valiant Organics Grants ESOPs at a Significant Discount Valiant Organics' NRC approved the grant of 18,000 ESOPs on 12 Aug'26 under its ESOP Scheme 2022. Each option is convertible into one equity share with a face value of ₹10. The exercise price is set at ₹10 per option, representing a significant discount to the market price. The options are exercisable within three years from the vesting date. This grant will lead to a minor equity dilution upon exercise but aims to retain key employee talent.
Intimation of the new corporate office
Others (Uncategorized) · 12 Aug 2026, 10:04 pm
Valiant Organics Q1FY27 Results and Key Corporate Updates Valiant Organics reported Q1FY27 consolidated net profit of ₹29.3 cr, up 257% YoY and 86% QoQ. Revenue grew 13.3% YoY to ₹231.5 cr. The Pharma division was a key driver, with segment profit of ₹16.9 cr versus a loss of ₹0.2 cr YoY. The board approved the re-appointment of Shri Sathiababu K. Kallada as Managing Director for a three-year term effective May 24, '27. The company also announced the shifting of its Registered and Corporate offices, subject to shareholder approval for the former.
Change in the Registered Office Address of the Company, subject to approval of the shareholders of the Company in the ensuing AGM.
Annual General Meeting · 12 Aug 2026, 10:02 pm
Re-appointment of a Managing Director, subject to approval of the shareholders of the Company in the ensuing AGM.
Change in Management · 12 Aug 2026, 9:59 pm
Please find our intimation in the captioned subject
Financial Result · 12 Aug 2026, 9:48 pm
Valiant Organics Q1 FY27 Results, MD Reappointment, and Office Relocation Valiant Organics reported Q1 FY27 consolidated net profit of ₹29.3 Cr, up 257% YoY. Revenue from operations for the quarter ended 30 Jun'26 was ₹231.5 Cr, a 13.3% YoY increase. Consolidated EPS stood at ₹10.44. The Board approved the re-appointment of Shri Sathiababu K. Kallada as Managing Director for a three-year term from 24 May'27. Additionally, the company is shifting its Registered Office to Tarapur, Boisar, and its Corporate Office to Vikhroli (West), Mumbai, subject to shareholder approval.
Approval of the unaudited financial results for the quarter ended June 30, 2026 and other matters
Outcome · 12 Aug 2026, 9:43 pm
Valiant Organics Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 23,154 (+13.3% YoY | +6.3% QoQ) ■ EBITDA: 4,162 (+67.4% YoY | +57.1% QoQ) ■ EBITDA Margin (%): 18.0 (+581 bps YoY | +581 bps QoQ) ■ PAT: 2,905 (+254.2% YoY | +84.8% QoQ) ■ EPS (INR): 10.4 (+256.3% YoY | +86.1% QoQ) Valiant Organics Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Speciality Chemical Division ■ Revenue: 17,574 (+16.6% YoY | +3.7% QoQ) ■ EBIT: 2,506 (+44.3% YoY | +17.0% QoQ) ■ EBIT Margin (%): 14.3 (+274 bps YoY | +162 bps QoQ) Pharma Division ■ Revenue: 5,580 (+3.9% YoY | +15.5% QoQ) ■ EBIT: 1,685 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 30.2 (Loss to Profit YoY | Loss to Profit QoQ)
Valiant Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve financial results for the ....
Intimation · 12 Aug 2026, 5:30 am
Valiant Organics Board Meeting on Aug 12, '26 to Approve Q1FY27 Results Valiant Organics has scheduled a Board of Directors meeting on Aug 12, '26, to consider and approve its unaudited standalone and consolidated financial results for the quarter ended Jun 30, '26. In connection with this, the trading window for dealing in the company's securities will remain closed until Aug 14, '26.
Please find our intimation in the captioned subject
Others (Uncategorized) · 07 Aug 2026, 1:13 am
Valiant Organics: CRISIL Upgrades Outlook to 'Stable', Reaffirms Ratings On 05 Aug'26, CRISIL revised its outlook on Valiant Organics' long-term bank facilities (Rs 370 crore) to 'Stable' from 'Negative' while reaffirming the rating at 'Crisil A-'. The short-term rating was reaffirmed at 'Crisil A2+'. The outlook revision reflects a strengthening business profile, supported by improved operating margins and steady revenue growth, driven by capacity ramp-up. For FY26, the company achieved revenue of Rs 745.68 crore and an operating margin of 12.75%, with continued improvement expected. The financial risk profile remains comfortable.
Please find attached our intimation in the captioned subject
Others (Uncategorized) · 07 Aug 2026, 1:03 am
Valiant Organics: CRISIL Upgrades Outlook to Stable, Reaffirms Ratings On 05 Aug'26, CRISIL revised its outlook on Valiant Organics' long-term bank facilities (Rs. 370 crore) to 'Stable' from 'Negative', reaffirming the rating at 'CRISIL A-'. The short-term rating was reaffirmed at 'CRISIL A2+'. The outlook revision is driven by an improved business risk profile, supported by higher operating margins and steady revenue growth from capacity ramp-ups. For fiscal '26, the company reported revenue of Rs. 745.68 crore with a 12.75% operating margin. Its financial risk profile remains comfortable.
Please find our intimation in the captioned subject
Others (Uncategorized) · 22 Jun 2026, 8:28 pm
Valiant Organics Allots 15,000 Shares Under ESOP 2022 Valiant Organics allotted 15,000 equity shares of Rs. 10 face value on 22 Jun'26 under its Employee Stock Option Plan 2022. The shares were issued at an exercise price of Rs. 10 per share. Consequently, the company's paid-up equity share capital increased from Rs. 28,01,96,100 to Rs. 28,03,46,100. The total number of fully paid-up equity shares now stands at 2,80,34,610. The new shares will rank pari-passu with existing equity shares, resulting in minor equity dilution.
Update on Postal Ballot process
Others (Uncategorized) · 18 Jun 2026, 10:45 pm
Valiant Organics Cancels Postal Ballot for Related Party Transaction Valiant Organics' Board of Directors, at its meeting on 18 Jun'26, decided not to proceed with the proposed transaction involving its cessation as a partner in Dhanvallabh Ventures LLP. Consequently, the material related party transaction is shelved for the time being. The company has cancelled the associated postal ballot process and withdrawn the electronic voting event (EVEN - 139390) initiated for shareholder approval. The Board will deliberate further on the matter.
Please find our attached intimation on the captioned subject.
Investor Presentation · 27 May 2026, 6:43 pm
Valiant Organics Reports Strong Turnaround and Margin Expansion in FY26 Valiant Organics reported a strong turnaround for FY26, with revenue up 2.8% YoY to INR 7,388 Mn. EBITDA grew 64.2% to INR 882 Mn, as margins expanded 447 bps to 11.94%, driven by cost optimization and lower raw material intensity. The company posted a PAT of INR 332 Mn, reversing a loss of INR 34 Mn in FY25. For Q4 FY26, revenue increased 6.9% YoY to INR 2,178 Mn, while EBITDA margin improved 221 bps YoY to 12.17%. PAT for the quarter stood at INR 157 Mn.